Allergy

In an interview during the 2024 AAAAI conference, Casale addressed his team’s findings regarding epinephrine nasal spray and its effectiveness with regard to exacerbations of urticaria.

Robert Wood, MD, principal investigator of the OUtMATCH trial, offers insight into the trial and its results beyond the primary outcome, with a focus on what it means for patients and providers.

Omalizumab, the only FDA-approved treatment for multiple food allergies, demonstrated significant efficacy in the OUtMATCH trial, with 67% achieving the primary outcome compared to 7% in the placebo group.

In this interview, Ebisawa discusses his team’s recent research into the frequently-discussed non-injector epinephrine alternative neffy.

This analysis, to be presented at AAAAI, suggests that adolescents’ attendance of daycare may lead to decreased IgE levels and diminished food and aeroallergen sensitization rates.

Robert Wood, MD, discusses how the FDA approval of omalizumab (Xolair) changes the management of pediatric food allergy and what type of hurdles to optimal uptake the community may encounter.

These data, to be presented at AAAAI, indicate that following 12 and 24 months of immunotherapy with BMOIT, desensitization to milk products can be observed among patients.

The approval is based upon phase 3 findings from the OUtMATCH study, representing the first treatment for adult and pediatric patients with accidental exposure to 1 or more food allergens.

For patients with chronic rhinosinusitis, seasonal allergies may only make the condition feel worse for patients, though the relationship is still poorly defined.

The findings in a recent phase 3 clinical study may allow Kalvista Pharma to seek FDA approval for this potential hereditary angioedema treatment option.

In this interview, Palmer shares several of the key findings and their implications for the future of this patient population.

This research points to the notion that omalizumab may help individuals in more ways than a reduction of their sinonasal symptoms.

This research into EDS-FLU is significant, as there remain no medications approved by the FDA for chronic rhinosinusitis without nasal polyps.

This research had been conducted to look into prior studies linking daily pollen counts to respiratory allergic health outcomes.

This study looked at results of DOC, allergy risk level risk distinctions, and rationale for families and physicians to move forward with DOC.

The seismic shifts in mentality for allergy management and the strides made in immunotherapy have kept parents of children with allergies hopeful, but changes are still needed.

From breakthroughs in disease intervention and vaccines, to global developments in air quality and COVID-19, Lungcast reflects on the people and stories that shaped this year in pulmonology.

This review of telehealth use among adolescents with allergic conditions synthesized evidence on patients’ transition to self-management of their conditions.

This research highlights the close relationship between pollen-induced allergic rhinitis, sensitization, and asthma.

This represented the first in human research focused on assessing the best dosing regimen of mannan-conjugated birch pollen allergoids for those with birch pollen–induced allergic rhinoconjunctivitis.

This new recommendation by the European Academy of Allergy and Clinical Immunology was put forward to help guide clinical practices.

Data show how care providers shifted their mindsets to prioritize efficacy, safety, tolerability and availability factors during the 2022 formula supply shortage and recall crises.

This new research could allow for limitations related to safety that could promote mitigation of ambient air pollution and protect those with allergies.

An institution's review of prescriptions in the first year since dupilumab's historic FDA approval for eosinopihlic esophagitis shows patients waited a mean 46 days to initiate the biologic therapy.

This new analysis was described as the first estimate on the prevalence in Europe of specific TNA and sensitization.